Akebia Therapeutics(NASDAQ) AKBA

Market Cap$241.86M

Since IPO (2014)-97%

5 Year-65%

1 Year-74%

1 Month-36%

$0.86

-1.65%

-0.01Today

After hours$0.86+$0.00 (+0.38%)

Akebia Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.86	2026-08-17

Akebia Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+1.9%	USD 0.84	2026-08-10
1 month	-35.82%	USD 1.34	2026-07-17
3 month	-3.92%	USD 0.90	2026-05-19
Year to date	-46.58%	USD 1.61	2025-12-31
1 year	-73.54%	USD 3.25	2025-08-15
3 year	-31.2%	USD 1.25	2023-08-18
5 year	-64.61%	USD 2.43	2021-08-18
Since inception	-96.73%	USD 26.70	2014-03-20

Akebia Therapeutics Financials at a Glance

Market Cap

$241.86M

Revenue (TTM)

$219.06M

Net Income (TTM)

-$29.67M

EPS (TTM)

-$0.11

P/E Ratio

-7.86

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Price

$0.86

Volume

4,263,932

Open

$0.87

Price

$0.86

Volume

4,263,932

Open

$0.87

Previous Close

$0.86

Daily Range

$0.81 - $0.88

52-Week Range

$0.81 - $3.32

Estimated Earnings Date

Nov 9, 2026

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Price

$0.86

Volume

4,263,932

Open

$0.87

Previous Close

$0.86

Daily Range

$0.81 - $0.88

52-Week Range

$0.81 - $3.32

Estimated Earnings Date

Nov 9, 2026

AKBA News

Page 1

AKBA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akebia Therapeutics

Akebia helps people who have serious kidney problems. Its medicines manage health issues like low red blood cell counts and high mineral levels. These treatments help patients feel better while they receive regular dialysis.

Managing Kidney Disease Needs

Auryxia: Oral medicine for controlling phosphorus in dialysis patients and treating iron deficiency anemia in others with chronic kidney disease.
Vafseo: Tablet for treating anemia in adults on dialysis; it works by helping the body make more red blood cells.
Riona: Ferric citrate product sold in Japan by a partner to treat high phosphorus levels and iron deficiency.

Strategic Moves and Deals

Acquired clinical-stage drug AKB-097 from Q32 Bio in November 2025 to expand into rare kidney disease treatments.
Ended a licensing deal with CSL Vifor in July 2024 to regain full U.S. commercial rights for its medicine Vafseo.
Secured an exclusive global license from Cyclerion in June 2021 for praliciguat, a drug candidate for kidney conditions.
Faced the market entry of a generic version of Auryxia from Teva Pharmaceuticals Ltd. in March 2026.

What Sets the Company Apart?

The company operates as a fully integrated biotech firm that handles both the scientific discovery and the sale of its own drugs. It maintains global reach through deep partnerships with international pharmaceutical leaders like Otsuka and Mitsubishi Tanabe Pharma.

By the Numbers

Total revenue was $53.5 million in Q1 2026, down 6.6% from $57.3 million in Q1 2025.
Net income fell to a loss of $9.1 million in Q1 2026, worsening by 248.1% from the previous year.
Free cash flow reached negative $21.2 million in Q1 2026, a 55.9% deepening in losses compared to Q1 2025.
Operating income dropped to a loss of $4.7 million in Q1 2026, worsening by 134.7% year-over-year.

Bottom Line

Akebia has evolved from a research-focused startup into a commercial-stage company with two flagship kidney treatments. While it faces new competition from generic drug makers, its focus on licensing new experimental therapies supports its long-term product pipeline.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

194

CEO

John P. Butler, MBA

Website

www.akebia.com

Headquarters

Cambridge, MA 02142, US

AKBA Financials

Key Financial Metrics (TTM)

Gross Margin

79.48%

Operating Margin

-6.91%

Net Income Margin

-13.54%

Return on Equity

-93.74%

Return on Capital

9.44%

Return on Assets

-8.48%

Earnings Yield

-12.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$241.86M

Shares Outstanding

277.11M

Volume

4.26M

Avg. Volume

5.20M

Financials (TTM)

Gross Profit

$174.10M

Operating Income

-$15.13M

EBITDA

-$18.01M

Operating Cash Flow

$41.55M

Capital Expenditure

-$1.38M

Free Cash Flow

$40.23M

Cash & ST Invst.

$155.55M

Total Debt

$53.96M

Akebia Therapeutics Performance Analysis

Akebia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 292,484,000	38.2%
2023	2023-12-31	USD 194,623,000	-33.5%
2024	2024-12-31	USD 160,180,000	-17.7%
2025	2025-12-31	USD 236,196,000	47.5%

Akebia Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-5.9%
Q4	2025-12-31	-2.0%
Q1	2026-03-31	-7.1%
Q2	2026-06-30	-8.2%

Akebia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.52	-69.7%
2023	2023-12-31	USD -0.28	-46.3%
2024	2024-12-31	USD -0.33	18.8%
2025	2025-12-31	USD -0.02	-93.7%

Akebia Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	122.2%
Q4	2025-12-31	-2405.0%
Q1	2026-03-31	26.5%
Q2	2026-06-30	11.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$49.13M

-21.4%

Gross Profit

$38.70M

-26.4%

Gross Margin

78.78%

N/A

Market Cap

$241.86M

N/A

Market Cap/Employee

$1.25M

N/A

Employees

194

N/A

Net Income

-$8.91M

-3706.5%

EBITDA

-$4.85M

-165.6%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$155.55M

+13.3%

Total Debt

$53.96M

+1.1%

Accounts Receivable

$53.51M

-26.5%

Inventory

$13.02M

-22.1%

Long Term Debt

$29.15M

-38.9%

Short Term Debt

$24.81M

+340.7%

Return on Assets

-8.48%

N/A

Return on Invested Capital

-8.01%

N/A

Free Cash Flow

$2.45M

-89.0%

Operating Cash Flow

$3.53M

-84.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GOSSGossamer Bio, Inc.

GOSSGossamer Bio, Inc.$0.14-9.21%

CMPXCompass Therapeutics, Inc.

CMPXCompass Therapeutics, Inc.$2.31+2.67%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$8.88+0.23%

ZVRAZevra Therapeutics, Inc.

ZVRAZevra Therapeutics, Inc.$11.53+1.86%

FDMT4D Molecular Therapeutics, Inc.

FDMT4D Molecular Therapeutics, Inc.$14.55+19.32%

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$42.45-0.31%

OLMAOlema Pharmaceuticals, Inc.

OLMAOlema Pharmaceuticals, Inc.$10.77+1.32%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.61-0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$146.23+0.04%

IPSTIp Strategy

IPSTIp Strategy$7.39+2.36%

NVDANvidia

NVDANvidia$225.01-0.00%

NOKNokia

NOKNokia$10.78+0.00%

INTCIntel

INTCIntel$103.49+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$8.69+0.02%

Questions About AKBA

What is the current price of Akebia Therapeutics?

Akebia Therapeutics is trading at $0.86 per share.

What is the 52-week range for Akebia Therapeutics?

Over the past 52 weeks, Akebia Therapeutics has traded between $0.81 and $3.32.

How much debt does Akebia Therapeutics have?

As of the most recent reporting period, Akebia Therapeutics reported total debt of $210.81M.

How much cash does Akebia Therapeutics have on hand?

Akebia Therapeutics reported $157.26M in cash and cash equivalents in its most recent financial results.

What is Akebia Therapeutics’s dividend yield?

Akebia Therapeutics does not currently have a dividend yield.

Akebia Therapeutics(NASDAQ) AKBA

Akebia Therapeutics Financials at a Glance

AKBA News

Akebia (AKBA) Q2 Revenue Jumps 43%

Why Shares of Akebia Therapeutics Were Up Tuesday

Why Akebia Therapeutics Stock Is Soaring Today

Why Akebia Therapeutics Stock Is Plunging Today

Why Akebia Therapeutics Stock Is Crashing Today

Why Akebia Therapeutics Stock Is Crushing It Today

2 Small-Cap Stocks That Could Double Your Money

Why Akebia Therapeutics Stock Sank Today

AKBA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Akebia Therapeutics

Managing Kidney Disease Needs

Strategic Moves and Deals

What Sets the Company Apart?

By the Numbers

Bottom Line

AKBA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Akebia Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AKBA

What is the current price of Akebia Therapeutics?

What is the 52-week range for Akebia Therapeutics?

How much debt does Akebia Therapeutics have?

How much cash does Akebia Therapeutics have on hand?

What is Akebia Therapeutics’s dividend yield?

Premium Investing Services